Amgen recently announced that the FDA has approved its supplemental Biologics License Application for the expanded use of Enbrel® (etanercept) to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. According to Amgen, Enbrel® is now “the first and only systemic therapy” for this indication, the approval of which was “based…